HomeCompareFBHS vs ABBV

FBHS vs ABBV: Dividend Comparison 2026

FBHS yields 10.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $80.8K in total portfolio value
10 years
FBHS
FBHS
● Live price
10.76%
Share price
$61.90
Annual div
$6.66
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$1.15
Full FBHS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FBHS vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFBHSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FBHS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FBHS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FBHS
Annual income on $10K today (after 15% tax)
$914.54/yr
After 10yr DRIP, annual income (after tax)
$0.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FBHS + ABBV for your $10,000?

FBHS: 50%ABBV: 50%
100% ABBV50/50100% FBHS
Portfolio after 10yr
$62.0K
Annual income
$12,386.46/yr
Blended yield
19.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FBHS
Analyst Ratings
18
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$86.55
+39.8% upside vs current
Range: $48.00 — $125.00
Altman Z
2.9
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FBHS buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFBHSABBV
Forward yield10.76%3.06%
Annual dividend / share$6.66$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$21.6K$102.3K
Annual income after 10y$1.15$24,771.77
Total dividends collected$1.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$86.55$256.15

Year-by-year: FBHS vs ABBV ($10,000, DRIP)

YearFBHS PortfolioFBHS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,238$537.96$11,550$430.00$312.00ABBV
2$12,307$282.51$13,472$627.96$1.2KABBV
3$13,313$144.57$15,906$926.08$2.6KABBV
4$14,318$73.08$19,071$1,382.55$4.8KABBV
5$15,357$36.73$23,302$2,095.81$7.9KABBV
6$16,451$18.41$29,150$3,237.93$12.7KABBV
7$17,611$9.21$37,536$5,121.41$19.9KABBV
8$18,849$4.61$50,079$8,338.38$31.2KABBV
9$20,170$2.31$69,753$14,065.80$49.6KABBV
10$21,584$1.15$102,337$24,771.77$80.8KABBV

FBHS vs ABBV: Complete Analysis 2026

FBHSStock

Fortune Brands Home & Security, Inc. provides home and security products for residential home repair, remodeling, new construction, and security applications. It manufactures, assembles, and sells faucets, accessories, kitchen sinks, and waste disposals under the Moen, ROHL, Riobel, Victoria+Albert, Perrin & Rowe, and Shaws brands in the United States, China, Canada, Mexico, Southeast Asia, Europe, and South America directly through its own sales force, as well as through independent manufacturers' representatives to wholesalers, home centers, mass merchandisers, and industrial distributors. The company also offers fiberglass and steel entry door systems under the Therma-Tru brand; storm, screen, and security doors under the Larson brand; composite decking and railing under the Fiberon brand; and urethane millwork under the Fypon brand. In addition, it manufactures, sources, and distributes locks, safety and security devices, and electronic security products under the Master Lock and American Lock brands; and fire resistant safes, security containers, and commercial cabinets under the SentrySafe brand. It serves home centers, hardware and other retailers, millwork building products and wholesale distributors, specialty dealers, and remodeling and renovation markets, as well as locksmiths, industrial and institutional users, and original equipment manufacturers in the United States, Canada, Europe, Central America, Japan, and Australia. Further, it manufactures custom, semi-custom, and custom cabinetry, as well as vanities for the kitchen, bath, and other parts of the home directly to kitchen and bath dealers, home centers, wholesalers, and builders in North America under the AOK, Diamond Brands, Homecrest, Kitchen Craft, Omega, and EVE brands. The company was incorporated in 1988 and is headquartered in Deerfield, Illinois.

Full FBHS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FBHS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FBHS vs SCHDFBHS vs JEPIFBHS vs OFBHS vs KOFBHS vs MAINFBHS vs JNJFBHS vs MRKFBHS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.